Navigation Links
Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
Date:7/15/2010

lex ways than one might have imagined. The panel did the best they could with data that weren't completely conclusive, that suggested an increased risk but didn't make it clear how much that increased risk was," he said.

And he explained, "The majority of the panel didn't feel the increased risk was enough to summarily remove a drug that hundreds of thousands of people are taking successfully."

A second heart expert agreed.

"I didn't think that the evidence was yet compelling enough to withdraw the product from the market," said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City. "It sounds like they're going to add some new warnings regarding the risk, and that seems like an appropriate step."

And such a step will likely decrease the use of Avandia, anyway, Garratt added. "Use went down pretty sharply after criticism started to fly and the presence of new boxed warnings will further depress the prevalence of this product in the marketplace," he said.

But Garratt also said he didn't think the experts' votes would end the controversy over Avandia.

"There is so much dissent within the FDA about the appropriate action to take with this drug that I can't imagine this will be the final world," he said. "Also, we've got an alternative product [Actos] that seems to be essentially as effective at controlling diabetes but hasn't been linked to the cardiovascular risks."

In a statement released after the vote, Dr. Ellen Strahlman, chief medical officer at GlaxoSmithKline, which makes Avandia, said, "Following today's recommendations, we will, of course, continue to work with the FDA in the best interest of diabetes patients ... Patients taking Avandia should speak with their physician about their treatment and any questions they may have regarding the safety of the medicine."

The FDA committee had been meeting intensively since early Tuesday morning, hearing di
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. FDA Panel Seems Skeptical Over Key Avandia Data
2. FDA Panel Appears Skeptical Over Key Avandia Data
3. Avandia Heart Risks Buried by Drug Company: Report
4. FDA Reviewer Questions Results of Key Avandia Trial
5. Latest Study on Diabetes Drug Avandia Finds No Heart Risks
6. Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude
7. Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
8. FDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the Market
9. FDA Says It Hasnt Decided Whether to Pull Diabetes Drug Avandia Off the Market
10. Remove Diabetes Drug Avandia From Market: FDA Documents
11. Remove Diabetes Drug Avandia From Market: FDA Reports
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
(Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
(Date:9/2/2015)... ... 02, 2015 , ... Chris Harrison of Harrison’s Footwear of Poulsbo announces the ... really,” says Chris. “We have a lot of repeat customers, and many of them ... for them—so we’ve given them the convenience of ordering from home.” , Harrison’s Footwear ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... Los Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... working to expand their fleet of truly superb luxury vehicles based on which of ... are pleased to announce the latest step forward in pursuit of this goal: a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and Mildred ... comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. Rutherford, ...
Breaking Medicine News(10 mins):Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3
... is helping to increase understanding about normal vaginal biology ... women prone to infections and other diseases, and ... suffer from insidious health problems, including bacterial vaginosis and ... to seek medical treatment, said Larry Forney, a professor ...
... times as much food as conventional farming on the ... refute the long-standing assumption that organic farming methods cannot ... ,Researchers from the University of Michigan found that ... and conventional farms. In developing countries, food production could ...
... found that children with Tourettes syndromean inherited neurological disorder ... learn certain mental grammar skills much faster than their ... at Georgetown University Medical Center and the Kennedy Krieger ... linked to tics in Tourettes syndrome may also result ...
... of Havana have found that two compounds from lobster ... properties. ,The researchers said that the compounds could ... and antiseptic properties, as well as to increase growth ... a very common polymer present in nature as part ...
... Laboratories announced primary results for its large-scale clinical ... non-hormonal, non-prescription Zestra(R) Feminine Arousal Fluid for ... study, designed and managed by David M. Ferguson, ... parallel design trial intended to expand on the ...
... day, the Australian police finally announced that the Dr.Mohammed ... charged with providing reckless support to terrorists by ... ,His cousin Sabeel Ahmed 26, who worked at Halton ... of having information that could have helped police prevent ...
Cached Medicine News:Health News:Vaginal Bacteria Vary Among Healthy Women 2Health News:Organic Farming Can Feed the World 2Health News:Organic Farming Can Feed the World 3Health News:Tourettes Syndrome in Children may also Result in Superior Learning Skills 2Health News:Lobster Shells Have Great Healing and Antiseptic Properties 2Health News:Study Shows Positive Results for Zestra(R) Feminine Arousal Fluid 2Health News:Three Doctors Charged So Far in the UK Bombing Case 2Health News:Three Doctors Charged So Far in the UK Bombing Case 3Health News:Three Doctors Charged So Far in the UK Bombing Case 4
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... Miss. , Sept. 2, 2015   Gulf Coast Tattoo ... removal services with the cutting-edge Astanza Duality laser in ... unwanted ink erase their tattoo regret and take back control of ... but extends its services to Biloxi ... region. "With tattoo regret being as prevalent as it ...
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ... "An Introduction to Medical Device Software: Regulations and ... conference to their offering. This ... regulations and requirements that apply to Medical Device ... real life examples and state-of- the-art practices identified ...
Breaking Medicine Technology:Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... and CAMPBELL, Calif. , May ... sophisticated risk characterization and personalized therapy guidelines for ... of advanced tests, offering an accompanying nutrition program, ... Director stated:  "With appropriate risk characterization and treatment, ...
... May 25 The U.S. Food and Drug Administration approved Lumizyme (alglucosidase ... a rare genetic disorder. , , ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , , , ... an estimated 1 in every 40,000 to 300,000 births. Its primary symptom is ...
Cached Medicine Technology:Health Network Laboratories (HNL) Enters Into License Agreement With Hunter Laboratories to Provide HunterHeart Cardiovascular Disease Management Program. 2FDA Approves New Treatment for Late-Onset Pompe Disease 2FDA Approves New Treatment for Late-Onset Pompe Disease 3
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... standby switch maintains power to the instrument without generating ... of 50 Hz separated by .75 s; repeats every ... Hz (2 pulses/s) , Tetanus: 50 Hz (50 ... pulses/2 s; repeats every 10 s , Output Current: ...
Medicine Products: